Last reviewed · How we verify

NCT03735329

Polso SpO2 Accuracy Validation Study

Completed NA Last updated 6 February 2019
What this trial tests

NA trial testing Diagnostic test of SPO2 in Hypoxia in 10 participants. Completed in 4 February 2019.

Timeline
29 January 2019
Primary endpoint
31 January 2019
4 February 2019

Quick facts

Lead sponsorChroniSense Medical Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment10
Start date29 January 2019
Primary completion31 January 2019
Estimated completion4 February 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

ChroniSense Medical Ltd.

Who can join

Adults 18 to 50, any sex, with Hypoxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to validate the oxygen saturation (SpO2) accuracy of the Polso Monitoring System during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry for SpO2 validation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypoxia

Currently open trials in the same condition.

Other ChroniSense Medical Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03735329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing